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Background: Schizophrenia is an invalid and severe neurodevelopmental disorder. The implication of vitamin D in the etiopathogenesis of schizophrenia shows through the activation of cellular and inflammatory pathways. It is especially vitamin D deficiency that has been associated with schizophrenia. It is within this framework that this study aims to explore the relationship between vitamin D levels and the clinical characteristics in a cohort of Tunisian patients with schizophrenia. Background: Electroconvulsive therapy (ECT) is the most popular way to stimulate brain for achieving therapeutic effects. The therapeutic effect of ECT results from the induction of a generalized seizure. The minimal amount of electrical energy needed to induce seizures is known as the seizure threshold (ST). It is commonly believed that treatment efficacy is related to stimulus dose relative to ST, but higher stimuli usually also increase unwanted side effects. Therefore, ST is an important issue in conducting ECT. Most patients including schizophrenics undergoing ECT take concomitant psychotropic drugs, but little information is available on how these drugs affect ST. Our study aimed to analyze the relationship between ST and psychotropic drugs in patients treated with ECT. Methods: We retrospectively reviewed the medical charts of 43 patients who received ECT at Korea University Guro Hospital between February 2009 and June 2015. Patients with a history of seizure disorders or other medical emergent conditions were excluded. A total of fifty-eight subjects received ECT during the study period. Patients were excluded if treatment was aborted due to side effects or any other reasons before the 10th session (n=12) because we intended to investigate the ST shift during the course of consecutive ECT sessions. We included 43 subjects in the final data analysis. Patients' psychiatric disorders were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-R) by at least two experienced psychiatrists. ECT was administrated with concurrent antipsychotics and antidepressants.67.4 percent of subjects were diagnosed as schizophrenia and 20.9 percent of subjects were diagnosed as major depressive disorder. We used stepwise multivariate correlation analyses for examining the associations between ST and psychotropic drugs. Data are presented as initial ST, the difference in ST between the first and 10th sessions (ΔST10th), and the mean difference in ST between the first and last sessions (mean ΔSTlast). We used chlorpromazine-equivalent dose for antipsychotics and fluoxetine-equivalent dose for antidepressants.
Results:
Of the 43 patients included in the study, 20 were male, and the other 23 were female. The mean age of all participants was 41.44 years (SD=15.89). Patients were taking the following antipsychotics and antidepressants: clozapine (n=6), amisulpride (n=9), aripiprazole (n=5), olanzapine (n=18), risperidone (n=1), quetiapine (n=20), haloperidol (n=1), paliperidone (n=5), chlorpromazine (n=1), blonanserin (n=1), escitalopram (n=7), sertraline (n=1), mirtazapine (n=2), duloxetine (n=1), venlafaxine (n=3), amitriptyline (n=1), trazodone (n=1), bupropion (n=1). Participants took an average of 1.91 (SD=1.02, range 0-5) different psychotropic drugs during ECT. The mean number of types of antipsychotics and antidepressants used were 1.53 (SD=0.74, range 0-3) and 0.37 (SD=0.76, range 0-4), respectively. Multivariate regression analyses showed positive correlations between initial ST and the total chlorpromazine-equivalent dose of antipsychotics (β = 0.363, p < 0.05). The total fluoxetine-equivalent dose of antidepressants was positively correlated to ΔST10th (β = 0.486, p < 0.05) and mean ΔSTlast (β = 0.472, p < 0.01). Discussion: Our study elucidated possible effects of psychotropic drugs on ST in patients undergoing ECT. We revealed that larger doses of antipsychotics are associated with higher initial ST, whereas higher doses of antidepressants are associated with stronger shifts of ST during the course of treatment. We believe that our findings provide a basis for creating safer and more efficient ECT protocols.
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Background: In the United States, the number of public and private psychiatric hospital beds has steadily declined in recent years, despite the lack of intensive intermediate care alternatives in the community. The design and implementation of intensive residential treatment programs are not currently guided by controlled studies, but these studies are necessary to determine the clinical and economic utility of such programs. We present clinical and outcome data on an initial sample of patients treated over the last 5 years. Methods: Naturalistic, non-controlled assessment of symptomatic and functional outcome in an initial sample of young adults with persistent mental illnesses treated in a community-based residential program. Patients were treated with an individualized combination of modalities such as Illness Education and Management, Supported Employment, Individual, Group and Family Psychotherapies and Psychopharmacology. Standard clinical rating scales were used during the period of treatment and all discharged patients were contacted on an annual basis in order to complete a survey of clinical outcome. Results: 101 patients had been admitted and treated since the facility opened in October 2011. Median age of the patients was 25 years, mean illness duration was 12.6 years, and the mean number of prior hospitalizations was 6.5. Diagnostic distribution was: 36.7% psychotic disorders, 27.7% unipolar mood disorders, 19.8% bipolar mood disorders, 7.9% autism spectrum disorders, and 7.9% post-traumatic stress disorder or other anxiety conditions. 37% of residents met criteria for personality disorders, the majority of which was borderline personality disorder. 42% of residents also met criteria for a substance use disorder in the year prior to admission. Ratings on the Multnomah Community Ability Scale improved by 16%, ratings on the Brief Psychiatric Rating Scale declined by 20% and ratings on the Montgomery-Asberg Depression Rating Scale declined by 37%. The average survey response rate after discharge was 59%. With regard to community engagement: 40.3% of current residents and 35.1% of discharged residents were competitively employed. 16.7% of current residents and 17.8% of discharged residents worked as volunteers, and 23.3% of current
